EMJ GOLD
@emg-gold
The latest pharma news, views and analysis. Sign up to our mailing list to receive insights direct to your inbox:
Has surgical robotics been due for a redesign? Johnson & Johnson's FDA-authorised OTTAVA™ system takes a different approach, with robotic arms integrated directly into the operating table. Read more: hubs.la/Q04qwtVR0 #SurgicalRobotics #MedTech #RoboticSurgery #MedicalInnovation
Novartis reports 3% sales growth as newer medicines help offset the sharp decline in sales of its blockbuster heart failure drug following patent expiry. Read more: www.emjreviews.com/emj-gold/new...
NICE has issued draft guidance backing Merck's #finerenone for HFpEF and HFmrEF. The nod could expand the therapy's use within the NHS, representing a significant milestone for heart failure treatment in England and Wales. Read more: www.emjreviews.com/emj-gold/new... #HeartFailure
Eli Lilly has announced plans to buy AtaiBeckley for up to $3.8bn, gaining access to a synthetic version of 5-MeO-DMT, the psychedelic compound associated with Colorado River toad venom. Read more: hubs.la/Q04pNhSx0 #PsychedelicMedicine
AstraZeneca's shopping trip in China continues. The company has struck a $1.5bn agreement with Shanghai's Dizal Pharmaceutical for global rights to sunvozertinib, a lung cancer therapy approved in the US and China. Learn more about the deal: www.emjreviews.com/emj-gold/new...
"The rise of GLP-1s is as much a cultural story as a medical one." In our latest column, Claire Gillis, CEO, #VMLHealth, explores the meteoric rise of #GLP1 therapies and how they could transform the medical landscape. Read it now: www.emjreviews.com/emj-gold/art... #Obesity
There's more to discover from our time at #EHA2026. We sat down with Ester in ’t Groen, TA Head, Haematology, J&J Innovative Medicine EMEA, to discuss the rapid evolution of #multiplemyeloma treatment and the innovations bringing new hope to patients. Watch now: www.emjreviews.com/emj-gold/art...
Couldn't make it to EHA 2026? We've got you covered. In Stockholm, we sat down with Aliya Omer, Global Head, Haematology Franchise, AstraZeneca, to discuss the innovations shaping the future of haematological cancer care. Watch now: www.emjreviews.com/emj-gold/art... #Haematology
A new epilepsy diagnosis is made every minute in Europe. In this episode, Rafal Kaminski, Chief Scientific Officer, Angelini Pharma, explores how scientific innovation is reshaping brain health, with a focus on epilepsy. Listen now: www.emjreviews.com/emj-gold/pod... #BrainHealth
💥New interview live now💥 Hear from Dr Siddharth Jain, Head, Global Medical Unit for Growth & Launch Brands for Rare Diseases, Takeda. He explores: - The future of medical affairs - What could transform rare disease care - And more! www.emjreviews.com/emj-gold/art... #RareDiseases #MedicalAffairs
What makes an HCP open an email? In our latest white paper, we asked HCPs exactly that. Their top priorities were: 📩 Clinical relevance 🤝 A trusted sender ✍️ A personalised subject line 📊 New evidence Discover more findings 👇 www.emjreviews.com/emj-gold/inf...
More than 100 emails land in the average HCP inbox each day. In a new white paper, we surveyed the audience to provide teams serious about improving their email strategy with a clearer picture of what truly works. 🔗 hubs.la/Q04jbt-x0 #PharmaMarketing #MedicalAffairs
“The science is moving faster than the regulatory system around it.” To celebrate #WorldClinicalTrialsDay, the team spoke to Muriel O’Byrne, Regeneron, about the opportunities and challenges shaping the future of clinical trials today. Read now: www.emjreviews.com/emj-gold/art...
The results are in 📣 It's time to see what held firm and what trends took shape. How did HCPs consume medical content in 2025? Find out now: www.emjreviews.com/emj-gold/inf... #pharmamarketing #medicalaffairs
“Sometimes I don’t understand why people would want to do something else.” Andrew Menzies-Gow, VP, #AstraZeneca, loves his job. In this interview, he talks diagnosis gaps, shifting COPD thinking and fixing care. Read now: www.emjreviews.com/emj-gold/art... #Respiratory #COPD #asthma
Calling all those in cancer care. In this new column, Dr Henar Hevia, J&J Innovative Medicine, explores how real-world evidence and better decision-making can improve outcomes, personalise treatment and close the gap between innovation and care. Read now: hubs.la/Q04cv8dL0
More from #WIREDHealth: Kathleen Fisher, CEO, ARIA, shared a story about failure. A synthetic blood programme didn’t work as intended. But the same technology showed potential elsewhere. It eventually led to Moderna’s mRNA platform. Sign up for more: www.emjreviews.com/mailing-list/
The team are at #WIREDHealth to capture the key insights for pharma. Top moment so far: Lord Vallance calls on UK funds to invest in life sciences, noting only Canadian funds, and pensioners, are currently reaping the rewards. Sign up for full round up: www.emjreviews.com/mailing-list/
Is CMS reshaping cannabinoid access policy through the back door? A new federal pilot allows Medicare organisations to discuss and furnish hemp-derived CBD products - without FDA approval and without going through standard regulatory process. 🔗: hubs.la/Q04bp4X70
Novo Nordisk has launched a 7.2 mg semaglutide injection in the US, nearly three times the previous highest available dose. Learn more: www.emjreviews.com/emj-gold/new...
Cardiovascular disease costs the world $680bn a year. A new OHE report suggests up to $480bn of that could be avoided. The key? Early detection and management of moderately elevated LDL-C at scale. Read more: www.emjreviews.com/emj-gold/new...
Think you're a medical affairs whizz? Test your knowledge with our brand new quiz! From the origins of the medical affairs to the modern challenges of omnichannel engagement, see how well you know pharma’s ever-evolving function. Take the quiz to see how you do: www.emjreviews.com/en-us/amj/em...
Think you’re a pharma marketing buff? Step back through 200 years of history with our new interactive quiz. From 19th-century origins to the rise of modern transparency, see how much you know about the shifts that shaped the function. Take the challenge: www.emjreviews.com/quiz-how-wel...
"Healthy ageing is not something we should postpone until retirement; it’s a lifelong process." In our latest interview, Dr Stefanie Rau, Nestlé Health Science, shares why healthy ageing matters, and why it’s never too early to invest in long-term health. 🔗 www.emjreviews.com/emj-gold/art...
Pharma Year in Review 2025 🌍 2025 was a year of incredible healthcare momentum balanced by regulatory challenges. Join Hanna Svanbäck, Jonathan Sackier, and Yacin Marzouki as they reflect on 2025. 🎧 Listen here: www.emjreviews.com/emj-gold/pod...
Welcome to Unwrapped! 🎄 We’re wrapping up 2025 with a special content series, reflecting on the past year in pharma. First up, try our tricky brain teaser challenge. What could it be? 🎁 Reveal the answer and explore more here: www.emjreviews.com/emj-gold/art...
In our latest Catalyst interview, medical affairs leader Dr Michael Zaiac, Daiichi Sankyo, discusses personalised medicine adoption, including the significant role that biomarkers and AI will play in the future of oncology. Watch the full interview: www.emjreviews.com/emj-gold/art...
Amid price cuts, tariff skirmishes and life-saving science, the biggest breakthroughs aren’t always found in the lab. In this month's news roundup, we unpack November’s top read stories, exploring not just what happened, but the why. Read now: www.emjreviews.com/emj-gold/new...